Читать книгу Metabolic Syndrome Consequent to Endocrine Disorders - Группа авторов - Страница 36

1Kamenicky P, Maziotti G, Lombes M, Giustina A, Chanson P: Growth hormone, insulin-like growth factor-1 and the kidney: pathophysiological and clinical implications. Endocr Rev 2014;35:234–281.

2Houssay BA: The hypophysis and metabolism. N Engl J Med 1936;214:961–971.

3Møller N, Jørgensen JO: Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009;30:152–177.

4O´Neill BT, Lauritzen HPMM, Hirschman MF, Smyth G, Goodyear LJ, Kahn CR: Differential role of insulin/IGF-1 receptor signaling in muscle growth and glucose homeostasis. Cell Report 2015;11:1220–1235.

5Muggeo M, Saviolakis GA, Businaro V, Valerio A, Moghetti P, Crepaldi G: Insulin receptor on monocytes from patients with acromegaly and fasting hyperglycemia J Clin Endocrinol Metab 1983;56:733–738.

6Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R: Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986;250:E269–E273.

7Frara S, Maffezzoni F, Mazziotti G, Giustina A: Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 2016;27:470–483.

8Smith TR, Elmendorf JS, David TS, Turinsky J: Growth hormone-induced insulin resistance: role of the insulin receptor, IRS-1, GLUT-1, and GLUT-4. Am J Physiol 1997;272:E1071–E1079.

9Nielsen C, Gormsen LC, Jessen N, Pedersen SB, Møller N, Lund S, Jørgensen JO: Growth hormone signaling in vivo in human muscle and adipose tissue: impact of insulin, substrate background, and growth hormone receptor blockade. J Clin Endocrinol Metab 2008;93:2842–3850.

10Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S, Kouhara H, Koga M, Saitoh Y, Ohnishi T, Arita N: Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 2000;52:549–555.

11Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, Galdiero M, Colao A: Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 2017;20:46–62.

12Aguilar C, Velázquez V, Gómez F, Gonzalez A, Lara A, Molina V, Rull J, Tapia R: Characteristics of patients with type 2 diabetes in Mexico. Results from a large population – based nationwide survey. Diabetes Care 2003;26:2021–2026.

13Unikrishnan R, Pradeepa R, Joshi SR, Mohon V: Type 2 diabetes: demystifying the global epidemic. Diabetes 2017;66:1432–1442.

14Biering H, Knoppe G, Lochs H: Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austr 2002;27:27–31.

15Stelmachovska-Banas M, Zdunowski P, Zgliczynski W: Abnormalities in glucose homeostasis in acromegaly. Does the prevalence of glucose intolerance depend on the level of activity of the disease and the duration of symptoms? Endocrynol Pol 2009;60:20–24.

16Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M: Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 2011;14:231–235.

17Dreval AV, Trigolosova IV, Misnikova IV, Kovalyova YA, Tishenina RS, Barsukov IA, Vinogradova AV, Wolffenbuttel BH: Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect 2014;3:93–98.

18Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M, Uribe-Diaz AM, García-Dominguez A, Reza-Albarrán AA, Cuevas-Ramos D, Melgar V, Talavera J, Rivera-Hernandez AJ, Valencia-Méndez CV, Mercado M: Mexican Acromegaly Registry Group: The Mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J Clin Endocrinol Metab 2016;101:3997–4004.

19Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P, Maiter D: Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014;17:81–89.

20Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C: The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013;98:E51–E59.

21Mercado M, Espinosa de los Monteros AL, Sosa E, Cheng S, Mendoza V, Hernandez I, Sandoval C, Guinto G, Molina M: Clinical-biohcemical correlations in acromegaly at diagnosis and the real prevalence of biochemically-discordant disease. Horm Res 2004;62:293–299.

22Bates AS, Evans AJ, Jones P, Clayton RN: Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf) 1995;42:417–423.

23Maione L, Brue T, Beckers A, Delemer B, Petrossians P, Borson-Chazot F, Chabre O, Francois P, Bertherat J, Cortet-Rudelli C, Chanson P: Changes in the management and comorbidities of acromegaly over three decades: the French acromegaly registry. Eur J Endocrinol 2017;176:645–655.

24Bates AS, Van’t Hoff W, Jones JM, Clayton RN: An audit of outcome of treatment in acromegaly. Q J Med 1993;86:293–299.

25Arosio M, Reimondo G, Malchiodi E, Berchialla P, Borraccino A, De Marinis L, Pivonello R, Grottoli S, Losa M, Cannavò S, Minuto F, Montini M, Bondanelli M, De Menis E, Martini C, Angeletti G, Velardo A, Peri A, Faustini-Fustini M, Tita P, Pigliaru F, Borretta G, Scaroni C, Bazzoni N, Bianchi A, Appetecchia M, Cavagnini F, Lombardi G, Ghigo E, Beck-Peccoz P, Colao A, Terzolo M; Italian Study Group of Acromegaly: Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 2012;167:189–198.

26Mercado M, Gonzalez B, Vargas G, Ramirez C, de los Monteros AL, Sosa E, Jervis P, Roldan P, Mendoza V, López-Félix B, Guinto G: Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic. J Clin Endocrinol Metab 2014;99:4438–4446.

27Giordano C, Ciresi A, Amato MC, et al: Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 2012;15:539–551.

28Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G: Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 2008;93:2639–2646.

29Kinoshita Y, Fujii H, Takeshita A, Taguchi M, Miyakawa M, Oyama K, Yamada S, Takeuchi Y: Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic {beta}-cell function is preserved. Eur J Endocrinol 2011;164:467–473.

30Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plöckinger U, Strowski MZ: Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. J Clin Endocrinol Metab 2007;92:673–680.

31Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A: Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009;94:1500–1508.

32Jonas C, Maiter D, Alexopoulou O: Evolution of Glucose Tolerance After Treatment of Acromegaly: A Study in 57 patients. Horm Metab Res 2016;48:299–305.

33Mercado M, Espinosa E, Ramírez C: Current status and future directions of pharmacological therapy for acromegaly. Minerva Endocrinol 2016;41:351–365.

34Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Fleseriu M, van der Lely AJ, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Sheppard M; Pasireotide C2305 Study Group: Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 2014;99:791–799.

35Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A; Pasireotide C2402 Study Group: Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:875–884.

36Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S: Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013;98:3446–3453.

37Chaves VE, Júnior FM, Bertolini GL: The metabolic effects of growth hormone in adipose tissue. Endocrine 2013;44:293–302.

38Stanley TL, Grinspoon SK: Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res 2015;25:59–65.

39Beentjes JA, van Tol A, Sluiter WJ, Dullaart RP: Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 2000;153:491–498.

40Arosio M, Sartore G, Rossi CM, Casati G, Faglia G, Manzato E: LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Italian Multicenter Octreotide Study Group. Atherosclerosis 2000;151:551–557.

41Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, Le-Roith D: Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res 2010;20:1–7.

42Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ: Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol (Oxf) 2002;56:303–311.

43Hodish I, Barkan A: Long-term effects of pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 2008;4:324–332.

44Olefsky JM, Glass CK: Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010;72:219–246.

45Tilg H, Moschen AR: Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature Rev Immunol 2006;6:772–783.

46Olarescu NC, Ueland T, Godang K, Lindberg-Larsen R, Jørgensen JO, Bollerslev J: Inflammatory adipokines contribute to insulin resistance in active acromegaly and respond differently to different treatment modalities. Eur J Endocrinol 2013;170:39–48.

47Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM: Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun 2001;16;288:1102–1107.

48Fernández-Real JM, López-Bermejo A, Casamitjana R, Ricart W: Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 2003;88:2714–2718.

49Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 2003;46:459–469.

50Ronchi CL, Corbetta S, Cappiello V, Morpurgo PS, Giavoli C, Beck-Peccoz P, Arosio M, Spada A: Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients. Eur J Endocrinol 2004;150:663–669.

51Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C: Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab 2012;97:2907–2915.

52Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ: Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 2003;149:331–335.

53Reyes-Vidal CM, Mojahed H, Shen W, Jin Z, Arias-Mendoza F, Fernandez JC, Gallagher D, Bruce JN, Post KD, Freda PU: Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment. J Clin Endocrinol Metab 2015;100:2946–2955.

Prof. Moises Mercado

Experimental Endocrinology Unit and Endocrinology Service

Sur 132, No. 142, Suite 210

Col. Las Américas, Mexico City 01120 (Mexico)

E-Mail moises.mercado@endocrinología.org.mx